BCYC Bicycle Therapeutics plc Stock Quote

BCYC [NASD]

Healthcare | Biotechnology | United Kingdom

Index	-	P/E	-	EPS (ttm)	-2.07	Insider Own	29.90%	Shs Outstand	19.43M	Perf Week	39.96%
Market Cap	568.83M	Forward P/E	-	EPS next Y	-2.82	Insider Trans	-0.98%	Shs Float	4.33M	Perf Month	47.94%
Income	-38.00M	PEG	-	EPS next Q	-0.47	Inst Own	42.90%	Short Float	7.68%	Perf Quarter	49.34%
Sales	11.80M	P/S	48.21	EPS this Y	-124.50%	Inst Trans	1.96%	Short Ratio	3.74	Perf Half Y	52.40%
Book/sh	5.64	P/B	5.02	EPS next Y	-24.40%	ROA	-28.80%	Target Price	27.75	Perf Year	146.52%
Cash/sh	7.45	P/C	3.80	EPS next 5Y	-	ROE	-42.70%	52W Range	10.26 - 31.09	Perf YTD	57.66%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-27.90%	52W High	-8.97%	Beta	-
Dividend %	-	Quick Ratio	9.60	Sales past 5Y	-	Gross Margin	-	52W Low	175.83%	ATR	1.89
Employees	72	Current Ratio	9.60	Sales Q/Q	533.30%	Oper. Margin	-	RSI (14)	74.97	Volatility	12.50% 6.92%
Optionable	No	Debt/Eq	0.13	EPS Q/Q	1.50%	Profit Margin	-	Rel Volume	1.72	Prev Close	29.96
Shortable	Yes	LT Debt/Eq	0.13	Earnings	Nov 05	Payout	-	Avg Volume	88.88K	Price	28.30
Recom	1.60	SMA20	37.05%	SMA50	41.04%	SMA200	59.51%	Volume	149,694	Change	-5.54%

Oct-12-20

Initiated

Cantor Fitzgerald

Overweight

$30

Jun-12-20

Initiated

Oppenheimer

Outperform

Apr-17-20

Initiated

H.C. Wainwright

Buy

$25

Nov-14-19

Initiated

ROTH Capital

Buy

$17

Sep-11-19

Upgrade

Goldman

Neutral → Buy

$14

Jun-17-19

Initiated

Piper Jaffray

Overweight

$20

Jun-17-19

Initiated

Jefferies

Buy

$22

Jun-17-19

Initiated

Goldman

Neutral

$14

Jun-17-19

Initiated

Canaccord Genuity

Buy

$22

Jan-14-21 07:00AM	Bicycle Therapeutics Announces Pipeline Progress Update Business Wire +28.46%
Jan-06-21 11:58PM	Is Bicycle Therapeutics (NASDAQ:BCYC) Using Debt In A Risky Way? Simply Wall St.
Dec-09-20 01:32PM	Is BCYC A Good Stock To Buy Now? Insider Monkey
Nov-24-20 06:59AM	Bicycle Therapeutics to Present at the 2020 Piper Sandler Healthcare Conference Business Wire
Nov-20-20 04:05PM	Bicycle Therapeutics Announces Settlement of Patent Dispute with Pepscan Systems B.V. Business Wire +5.15%
Nov-12-20 04:01PM	Bicycle Therapeutics to Present at the Jefferies Virtual London Healthcare Conference Business Wire +10.36%
Nov-09-20 06:59AM	Bicycle Therapeutics Presents Posters at the SITC 35th Anniversary Annual Meeting Business Wire
Nov-08-20 07:17AM	Bicycle Therapeutics plc (NASDAQ:BCYC) Released Earnings Last Week And Analysts Lifted Their Price Target To US$27.71 Simply Wall St.
Nov-05-20 06:59AM	Bicycle Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update Business Wire
Oct-21-20 06:59AM	Bicycle Therapeutics Announces Expansion of Scientific Advisory Board Business Wire
Oct-14-20 05:08PM	Bicycle Therapeutics to Present Posters at the SITC 35th Anniversary Annual Meeting Business Wire
Oct-01-20 08:06AM	Bicycle Therapeutics Announces Gross Proceeds of $50.0 Million from its At-the-Market Offering Program and Enters into Debt Financing from Hercules Capital Business Wire
Sep-19-20 08:03AM	Revenue Downgrade: Here's What Analysts Forecast For Bicycle Therapeutics plc (NASDAQ:BCYC) Simply Wall St.
Sep-18-20 07:30AM	The Daily Biotech Pulse: Roche's COVID Combo Therapy Reduces Need For Ventilation, ESMO Presentations Benzinga
Sep-14-20 06:59AM	Bicycle Therapeutics to Present Trials in Progress Poster for BT8009 at the ESMO Virtual Congress 2020 Business Wire +21.92%
Sep-10-20 04:05PM	Bicycle Therapeutics Announces First Patient Dosed in Phase I/II Trial of Bicycle® Toxin Conjugate BT8009 in Patients with Advanced Solid Tumors Business Wire
Sep-03-20 06:59AM	Bicycle Therapeutics to Participate in Upcoming Virtual Investor Conferences Business Wire
Sep-02-20 06:59AM	Bicycle Therapeutics Announces First Patient Dosed in Phase IIa Trial of Bicycle® Toxin Conjugate BT1718 Business Wire
Sep-01-20 06:59AM	Bicycle Therapeutics Announces First Patient Dosed in Oxurions Phase II Trial Using a Novel Bicycle®-based Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema Business Wire
Aug-06-20 08:03AM	Investors Who Bought Bicycle Therapeutics (NASDAQ:BCYC) Shares A Year Ago Are Now Up 122% Simply Wall St.
Aug-05-20 04:05PM	Bicycle Therapeutics to Present at the Canaccord Genuity 40th Annual Growth Conference Business Wire
06:59AM	Bicycle Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update Business Wire
Jun-24-20 08:37AM	Bicycle Therapeutics (BCYC) Catches Eye: Stock Jumps 8.9% Zacks
Jun-23-20 06:59AM	Bicycle Therapeutics Appoints Sir Keith Peters as Chairman of Its Scientific Advisory Board Business Wire +8.91%
Jun-22-20 06:59AM	Bicycle Therapeutics Presents New Translational Data for BT5528 and Preclinical Data for Tumor-targeted Immune Cell Agonists at AACR Virtual Annual Meeting II Business Wire
Jun-13-20 07:56AM	Is Bicycle Therapeutics Stock a Buy? Motley Fool
Jun-12-20 06:46PM	Hedge Funds Are Buying Bicycle Therapeutics plc (BCYC) Insider Monkey
May-27-20 06:59AM	Bicycle Therapeutics to Present at Upcoming Investor Conferences Business Wire -7.14%
May-15-20 06:59AM	Bicycle Therapeutics to Present New Translational Research for BT5528 and Preclinical Data for Tumor-targeted Immune Cell Agonists at the AACR Virtual Annual Meeting II Business Wire
May-13-20 05:09PM	Bicycle Therapeutics to Present Trials in Progress Poster for BT5528 at the 2020 American Society of Clinical Oncology Virtual Meeting Business Wire
May-12-20 06:59AM	Bicycle Therapeutics Announces Publication of BT5528 Mechanism of Action in AACR Journal Molecular Cancer Therapeutics Business Wire
May-08-20 09:32AM	Growth Investors: Industry Analysts Just Upgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Revenue Forecasts By 26% Simply Wall St.
May-07-20 06:59AM	Bicycle Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update Business Wire
May-06-20 06:59AM	Bicycle Therapeutics to Present at the Bank of America 2020 Health Care Conference Business Wire
May-05-20 06:59AM	Bicycle Therapeutics Announces First Patient Dosed in Phase I Dose Escalation of BT5528 in Combination with Nivolumab Business Wire
Apr-23-20 06:59AM	Bicycle Therapeutics Appoints Zafar Qadir as General Counsel Business Wire
Apr-08-20 07:16AM	Bicycle Therapeutics Sees Hammer Chart Pattern: Time to Buy? Zacks
Apr-07-20 06:59AM	Bicycle Therapeutics Announces Pipeline Progress Update Business Wire
Apr-06-20 06:59AM	Bicycle Therapeutics to Participate in a Panel Discussion at the Canaccord Genuity Horizons in Oncology Conference Business Wire +5.13%
Mar-31-20 07:22AM	Need To Know: Analysts Are Much More Bullish On Bicycle Therapeutics plc (NASDAQ:BCYC) Simply Wall St.
Mar-30-20 11:30AM	Has Bicycle Therapeutics PLC Sponsored (BCYC) Outpaced Other Medical Stocks This Year? Zacks +8.14%
Mar-17-20 06:45AM	Companies Like Bicycle Therapeutics (NASDAQ:BCYC) Are In A Position To Invest In Growth Simply Wall St. -16.92%
Mar-16-20 08:38AM	Top Ranked Momentum Stocks to Buy for March 16th Zacks -10.89%
Mar-13-20 12:00PM	Bicycle Therapeutics PLC Sponsored ADR (BCYC) Upgraded to Buy: What Does It Mean for the Stock? Zacks -5.93%
11:30AM	Is Bicycle Therapeutics PLC Sponsored (BCYC) Outperforming Other Medical Stocks This Year? Zacks
10:18AM	Top Ranked Momentum Stocks to Buy for March 13th Zacks
Mar-10-20 06:59AM	Bicycle Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Corporate Updates Business Wire +21.29%
Feb-25-20 06:59AM	Bicycle Therapeutics Announces Exclusive Strategic Collaboration with Genentech to Develop and Commercialize Bicycle®-based Immuno-oncology Therapies Business Wire
Jan-07-20 07:00AM	Bicycle Therapeutics and Cancer Research UK to Collaborate on Development of New Bicycle® Immuno-oncology Candidate, BT7401 Business Wire +10.47%
Dec-22-19 06:09PM	Is Bicycle Therapeutics plc (BCYC) Going to Burn These Hedge Funds? Insider Monkey
Nov-26-19 07:00AM	Bicycle Therapeutics to Present at the Piper Jaffray 31st Annual Healthcare Conference TEST Business Wire Releases
07:00AM	Bicycle Therapeutics to Present at the Piper Jaffray 31st Annual Healthcare Conference Business Wire
Nov-14-19 07:00AM	Bicycle Therapeutics to Present at the Jefferies 2019 London Healthcare Conference Business Wire +8.65%
Nov-13-19 07:00AM	Bicycle Therapeutics Announces First Patient Dosed in Phase I/II Trial of Bicycle® Toxin Conjugate BT5528 in Patients with Advanced Solid Tumors Business Wire +5.84%
Nov-07-19 07:00AM	Bicycle Therapeutics Reports Third Quarter 2019 Financial Results and Corporate Update Business Wire
Nov-05-19 08:14AM	Bicycle Therapeutics to Present New Preclinical Data on BT7480, a Novel, Fully Synthetic Bicycle® Tumor-targeted Immune Cell Agonist, at the Society for Immunotherapy of Cancers 2019 Annual Meeting Business Wire -12.61%
Oct-31-19 07:00AM	Bicycle Therapeutics Announces Appointment of Veronica Jordan, Ph.D., to Board of Directors Business Wire
Oct-29-19 07:00AM	Bicycle Therapeutics Announces Appointment of Nigel Crockett, Ph.D., as Chief Business Officer Business Wire
Oct-22-19 03:00AM	Bicycle Therapeutics Expands Neuroscience Collaborations to Include Oxford Universitys Oxford Drug Discovery Institute Business Wire
Oct-16-19 04:33PM	Bicycle Therapeutics to Present New Translational Data for BT1718 and Preclinical Data for Other Bicycle® Toxin Conjugates at AACR-NCI-EORTC 2019 Business Wire
Sep-28-19 06:00AM	Bicycle Therapeutics Announces Presentation of Updated Data from Phase I/IIa Trial Evaluating BT1718 in Patients with Advanced Solid Tumors at ESMO 2019 Annual Congress Business Wire
Sep-24-19 07:00AM	Bicycle Therapeutics to Present Updated Data from Phase I/IIa Trial Evaluating Lead Asset BT1718 in Patients with Advanced Solid Tumors at ESMO 2019 Annual Congress Business Wire
Sep-19-19 09:23AM	When Will Bicycle Therapeutics plc (NASDAQ:BCYC) Run Out Of Cash? Simply Wall St. -15.90%
Aug-08-19 07:00AM	Bicycle Therapeutics Reports Second Quarter 2019 Financial Results and Provides Clinical Update Business Wire
Jul-24-19 08:00AM	Bicycle Therapeutics Enhances Board of Directors Business Wire
Jul-01-19 07:46AM	Bicycle Therapeutics shares soar 29% premarket on news of positive trial of DME treatment MarketWatch
07:30AM	Bicycle Therapeutics Announces Positive Topline Results from Oxurions Phase I Trial Using a Novel Bicycle-based Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema Business Wire
May-23-19 01:09PM	Bicycle Therapeutics shares slide 10.7% in trading debut MarketWatch
09:15AM	Guest Host Tonight and Tomorrow Zacks
08:55AM	Bicycle Therapeutics raises $60.2 million in IPO, Ideaya Biosciences raises $50 million MarketWatch
May-22-19 09:49PM	Bicycle Therapeutics Announces Pricing of Initial Public Offering Business Wire
May-21-19 04:45PM	Bicycle Therapeutics IPO: What You Need To Know Benzinga

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/IIa clinical trial targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase I clinical trials for the treatment of diabetic macular edema. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. Bicycle Therapeutics plc has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. The company was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lee Kevin	Chief Executive Officer	Jan 15	Sale	27.01	5,000	135,050	265,085	Jan 15 04:40 PM
Kalowski Lee	President and CFO	Jan 14	Option Exercise	1.60	10,000	16,000	10,000	Jan 15 04:44 PM
Kalowski Lee	President and CFO	Jan 14	Sale	25.00	10,000	250,000	0	Jan 15 04:44 PM
Lee Kevin	Chief Executive Officer	Jan 14	Sale	25.00	5,000	125,000	270,085	Jan 15 04:40 PM
Kalowski Lee	President and CFO	Dec 01	Option Exercise	1.56	7,500	11,700	7,500	Dec 03 08:53 PM
Kalowski Lee	President and CFO	Dec 01	Sale	22.50	7,500	168,750	0	Dec 03 08:53 PM
Kalowski Lee	President and CFO	Nov 27	Option Exercise	1.56	530	827	530	Nov 30 04:42 PM
Kalowski Lee	President and CFO	Nov 27	Sale	20.00	530	10,600	0	Nov 30 04:42 PM
Kalowski Lee	President and CFO	Nov 25	Option Exercise	1.56	9,781	15,258	9,781	Nov 25 08:31 PM
Kalowski Lee	President and CFO	Nov 25	Sale	20.07	9,781	196,305	0	Nov 25 08:31 PM
Kalowski Lee	President and CFO	Nov 23	Option Exercise	1.56	17,189	26,815	17,189	Nov 25 08:31 PM
Kalowski Lee	President and CFO	Nov 23	Sale	19.83	17,189	340,805	0	Nov 25 08:31 PM
GLAXOSMITHKLINE PLC	10% Owner	Jul 15	Sale	19.40	3,147	61,045	1,910,531	Sep 18 12:04 PM
GLAXOSMITHKLINE PLC	10% Owner	Jul 14	Sale	19.27	1,597	30,781	1,913,678	Sep 18 12:04 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience